Cytostatic and antiviral activity evaluations of hydroxamic derivatives of some non-steroidal anti-inflammatory drugs

Chemical Biology and Drug Design

Volumn 73, Issue 3, 2009, Pages 328-338

  Rajic, Zrinka ^a   Butula, Ivan ^a   Zorc, Branka ^a   Kraljevic Pavelic, Sandra ^b   Hock, Karlo ^b   Pavelic, Kresimir ^b   Naesens, Lieve ^c   De Clercq, Erik ^c   Balzarini, Jan ^c   Przyborowska, Monika ^d   Ossowski, Tadeusz ^d   Mintas, Mladen ^e  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b RUDER BO KOVI INSTITUTE   (Croatia)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d UNIVERSITY OF GDA SK   (Poland)

^e UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Antitumor agents; NSAID hydroxamic acids; Tumor cells: effectors of apoptosis

Indexed keywords

1 (4 CHLOROBENZOYL) N HYDROXY 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; 4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; 9 (2,3 DIHYDROXYPROPYL)ADENINE; AMANTADINE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; HYDROXAMIC ACID DERIVATIVE; N BENZYLOXY 1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOLE 3 ACETAMIDE; N BENZYLOXY 2 (3 PHENOXYPHENYL)PROPANAMIDE; N BENZYLOXY 2 (4 ISOBUTYLPHENYL)PROPANAMIDE; N HYDROXY 2 (3 PHENOXYPHENYL)PROPANAMIDE; N HYDROXY 2 (4 ISOBUTYLPHENYL)PROPANAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; RIBAVIRIN; RIMANTADINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOSTASIS; DRUG INHIBITION; DRUG SCREENING; DRUG SYNTHESIS; ELECTRIC POTENTIAL; FIBROBLAST; HELA CELL; HUMAN; HUMAN CELL; INFLUENZA VIRUS; PHARMACOPHORE; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CYTOSTATIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HUMANS; HYDROXAMIC ACIDS; INFLUENZA A VIRUS;

ORTHOMYXOVIRIDAE;

EID: 60349106619     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2009.00774.x     Document Type: Article

References (41)

1. Kleemann E.A., Engel J., Kutscher B., Reichert D. (2001) Pharmaceutical Substances, Synthesis, Patents, Applications. Stuttgart : Thieme.
2. Flynn D.L., Capiris T., Cetenko W.J. (1990) Nonsteroidal anti-inflammatory drug hydroxamic acids. Dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J Med Chem 33 : 2070 2072.
3. Cetenko W.A., Connor D.T., Flynn D.L., Sircar J.C. (1990) Novel hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition. EP 0 342,682, A2, 23 Nov 1989; ref. Chem Abstr 112 : 216688j.
4. Muri E.M.F., Nieto M.J., Sindelar R.D., Williamson J.S. (2002) Hydroxamic acids as pharmacological agents. Current Med Chem 9 : 1631 1653.
5. Boznar B., Zmitek J., Kocjan D. (1986) Process for the production of 2-(4-isobutylphenyl)-propiohydroxamic acid. 830,825, 1974, Chem Abstr; 85:62817k, E.P. 0 203 379 A1, 1986, ref. Chem Abstr 106 : 84185g.
6. Cetenko W.A., Connor D.T., Flynn D.L., Sircar J.C. (1990) Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase inhibition. U.S. 4,943,587. Chem Abstr 112 : 216688j.
7. De Martiis F., Arrigoni-Martelli E., Tamietto T. (1971) Antiinflammatory, antipyretic, and analgesic 2-methyl-5-methoxy-3-indoleacetohydroxamic acids. US 3624103, 30 Nov 1971; ref. Chem Abstr 76 : 72402z.
8. Orzalesi G., Selleri R., Caldini O., Volpato I., Innocenti F., Colome J., Sacristan A., Varez G. (1977) Ibuproxam and ibuprofen, a pharmacological comparison. Arzneim Forsch Drug Res 27 : 1006 1012.
9. Sloan K.B., Little R. (1982) Mannich-base hydroxamic acid prodrugs for the improved delivery of nonsteroidal antiinflammatory agents and a pharmaceutical composition containing them. EP 39051 A2, 4 Nov 1981; ref. Chem Abstr 96 : 104087g.
10. Summers J.B., Gunn B.P., Martin J.G., Mazdiyasni H., Stewart A.O., Young P.R., Goetze A.M., Bouska J.B., Dyer R.D. (1988) Orally active hydroxamic acid inhibitors of leukotriene biosynthesis. J Med Chem 31 : 3 5.
11. Thun M.J., Henley S.J., Patrono C.J. (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues. J Nat Cancer Inst 94 : 252 266.
12. Richter M., Weiss M., Weinberger I., Fürstenberger G., Marian B. (2001) Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis 22 : 17 25.
13. Gwyn K., Sinicrope F.A. (2002) Chemoprevention of colorectal cancer. Am J Gastroenterol 97 : 13 21.
14. Husain S.S., Szabo I.L., Tarnawski A.S. (2002) NSAID inhibition of GI cancer growth: clinical implications and molecular mechanism of action. Am J Gastroenterol 97 : 542 553.
15. Sivak-Sears N.R., Schwartzbaum J.A., Miike R., Moghadassi M., Wrensch M. (2004) Case-control study of use of nonsteroidal antiinflammatory drugs and glioblastoma multiforme. Am J Epidemiol 159 : 1131 1139.
16. Odake S., Morikava T., Tsuchiya M., Imamura L., Kobashi K. (1994) Inhibition of Helicobacter pylori urease activity by hydroxamic acid derivatives. Biol Pharm Bull 17 : 1329 1332.
17. Nandy P., Lien E.J., Avramis V.I. (1999) Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis. Anticancer Res 19 : 1625 1633.
18. Turbanti L., Cerbai G., Di Bugno C., Giorgi R., Garzelli G., Criscuoli M., Renzetti A.R., Subissi A., Bramanti G. (1993) 1,2-Cyclomethylenecarboxylic monoamide hydroxamic derivatives. A novel class of non-amino acid angiotensin converting enzyme inhibitors. J Med Chem 36 : 699 707.
19. Whittaker M., Floyd C.D., Brown P., Gearing A.J.H. (1999) Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 99 : 2735 2776.
20. Tarnawski A.S., Jones M.K. (2003) Inhibition of angiogenesis by NSAIDs: molecular mechanisms and clinical implications. J Mol Med 81 : 627 636.
21. Hung W.C., Chang H.C., Pan M.R., Lee T.-H., Chuang L.-Y. (2000) Induction of p27Kip1 as a mechanism underlying NS398-induced growth inhibition inhuman lung cancer cells. Mol Pharmacol 58 : 1398 1403.
22. Yasui H., Hideshima T., Ikeda H., Ocio E.M., Kiziltepe T., Vallet S., Okawa Y., Neri P., Sukhdeo K., Podar K., Chauhan D., Richardson P.G., Raje N., Carrasco D.R., Anderson K.C. (2007) Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of β-catenin/TCF pathway. Leukemia 21 : 535 540.
23. Zorc B., Antolic S., Butula I. (1993) Macromolecular prodrugs. I. Synthesis of some non-steroidal anti-inflammatory drug esters. Acta Pharm 43 : 127 133.
24. Zorc B., Butula I. (1994) Macromolecular prodrugs. III. Esters of fenoprofen and probenecid. Acta Pharm 44 : 103 108.
25. Kostrowicki T.J., Liwo A. (1990) Determination of equilibrium parameters by minimization of an extended sum of squares. Talanta 37 : 645 650.
26. De Clercq E., Balzarini J., Torrence P.F., Mertes M.P., Schmidt C.L., Shugar D., Barr P.J., Jones A.S., Verhelst G., Walker R.T. (1981) Thymidylate synthetase as target enzyme for the inhibitory activity of 5-substituted 2′-deoxyuridines on mouse leukemia L1210 cell growth. Mol Pharmacol 19 : 321 330.
27. 13C NMR study, cytostatic and antiviral evaluation. Bioorg Med Chem 13 : 131 139.
28. Denkert C., Fürstenberg A., Daniel P.T., Koch I., Köbel M., Weichert W., Siegert A., Hauptmann S. (2003) Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene 22 : 8653 8661.
29. Detjen K.M., Welzel M., Wiedenmann B., Rosewicz S. (2003) Nonsteroidal anti-inflammatory drugs inhibit growth of human neuroendocrine tumour cells via G1 cell-cycle arrest. Int J Cancer 107 : 844 853.
30. Kraljevic S., Stambrook P.J., Pavelic K. (2004) Accelerating drug discovery. EMBO Rep 5 : 837 842.
31. Kraljevic S., Sedic M., Scott M., Gehrig P., Schlapbach R., Pavelic K. (2006) Casting light on molecular events underlying anti-cancer drug treatment: what can be seen from the proteomics point of view? Cancer Treat Rev 32 : 619 629.
32. Takada Y., Bhardwaj A., Potdar P., Aggarwal B.B. (2004) Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-κB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 23 : 9247 9258.
33. Waskewich C., Blumenthal R.D., Li H., Stein R., Goldenberg D.M., Burton J. (2002) Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 62 : 2029 2033.
34. Marjanovic M., Zorc B., Pejnovic L., Kralj M. (2007) Fenoprofen and ketoprofen amides as potential antitumor agents. Chem Biol Drug Design 69 : 222 226.
35. Li J.Y., Wang X.Z., Chen F.L., Yu J.P., Luo H.S. (2003) Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line. World J Gastroenterol 9 : 915 920.
36. zur Hausen H. (1999) Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes. Semin Cancer Biol 9 : 405 411.
37. Goodwin E.C., DiMaio D. (2000) Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci USA 97 : 12513 12518.
38. Sima N., Wang S., Wang W., Kong D., Xu Q., Tian X., Luo A., Zhou J., Xu G., Meng L., Lu Y., Ma D. (2007) Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Gynecol Oncol 106 : 299 304.
39. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L., Williams J., Lengauer C., Kinzler K.W., Vogelstein B. (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104 : 263 269.
40. Jin Z., El-Deiry W.S. (2005) Overview of cell death signalling pathways. Cancer Biol Ther 4 : 139 163.
41. Bauman D.R., Rudnick S., Szewczuk L.M., Jin Y., Gopishetty S., Penning T.M. (2005) Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: Potential antineoplastic agents that work independently of cyclooxygenase isozymes. Mol Pharmacol 67 : 60 68.